TY  - GEN
AU  - Lieu,Christopher H
AU  - Hidalgo,Manuel
AU  - Berlin,Jordan D
AU  - Ko,Andrew H
AU  - Cervantes,Andres
AU  - LoRusso,Patricia
AU  - Gerber,David E
AU  - Eder,J Paul
AU  - Eckhardt,S Gail
AU  - Kapp,Amy V
AU  - Tsuhako,Amy
AU  - McCall,Bruce
AU  - Pirzkall,Andrea
AU  - Uyei,Anne
AU  - Tabernero,Josep
TI  - A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS
SN  - 1549-490X
PY  - 2018///0521
KW  - Acneiform Eruptions
KW  - epidemiology
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - pharmacology
KW  - Asthenia
KW  - Azetidines
KW  - Colorectal Neoplasms
KW  - drug therapy
KW  - Dose-Response Relationship, Drug
KW  - Drug Eruptions
KW  - ErbB Receptors
KW  - antagonists & inhibitors
KW  - Female
KW  - Humans
KW  - Hypokalemia
KW  - Immunoglobulin G
KW  - MAP Kinase Kinase 1
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Piperidines
KW  - Prospective Studies
KW  - Proto-Oncogene Proteins p21(ras)
KW  - genetics
KW  - Receptor, ErbB-3
KW  - Signal Transduction
KW  - drug effects
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study
UR  - https://doi.org/10.1634/theoncologist.2017-0175
ER  -